Bioymifi is able to promote cell death without the need for the Smac mimetic in T98G cells. At a 10 μM concentration, bioymifi induces processing of caspase-3 into smaller fragments. Caspase-8 and the related extrinsic apoptotic pathway are essential for bioymifi-induced cell death. Bioymifi induces DR5-dependent death pathways and is independent of TRAIL. Bioymifi binds the ECD of DR5 with a Kd of 1.2 μM but shows little binding affinity to the DR4 ECD. It has poor solubility in buffer solutions. Bioymifi promotes apoptosis by directly binding to and facilitating aggregation of DR5. When bioymifi reaches micromolar concentration, its capability to aggregate DR5 is strong enough to induce apoptosis in various cancer cells.
Cell Experiment | |
---|---|
Cell lines | Human glioblastoma (T98G) cells |
Preparation method | Dose-response curves of bioymifi and A2C2 in T98G cells are plotted as a function of A2C2 or bioymifi concentration. Human glioblastoma (T98G) cells are treated with various concentrations of A2C2 or bioymifi alone or in combination with 1 μM Smac mimetic (SM) for 48 h. The corresponding cell survival is normalized to the treatment without A2C2 or bioymifi. |
Concentrations | 0, 0.3, 1, 3, 10, 30 μM |
Incubation time | 48 h |
Animal Experiment | |
---|---|
Animal models | |
Formulation | |
Dosages | |
Administration |
Molecular Weight | 494.32 |
Formula | C22H12BrN3O4S |
CAS Number | 1420071-30-2 |
Solubility (25°C) | DMSO 10 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Wang G Nat Chem Biol. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells.
Related TNF Receptor Products |
---|
Chilob7/4
Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies. |
VIB4920
VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates. |
ABBV-428
ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors. |
TNF-α (31-45), human
TNF-α (31-45), human is a potent NF-kB pathway activator. |
LEESGGGLVQPGGSMK
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.